BioAge Labs to Present at Notable Healthcare Conference
BioAge Labs, Inc. (NASDAQ: BIOA), a promising clinical-stage biotechnology company, is preparing to share its innovative research at an important global healthcare conference. This event is an excellent opportunity for BioAge to showcase its commitment to developing treatments that target the biology of human aging and metabolic diseases.
Event Details
Scheduled for November 17 to 20, the Jefferies Global Healthcare Conference in London will feature key presentations from BioAge's leadership team. The CEO and co-founder, Kristen Fortney, and CFO, Dov Goldstein, are set to engage in a fireside chat from 7:30 AM to 7:55 AM ET on the first day of the conference. This session aims to provide profound insights into the company’s vision and ongoing projects.
Innovations in Metabolic Disease Research
BioAge Labs is at the forefront of biopharmaceutical advancement, focusing on therapeutic product candidates that could significantly change treatments for metabolic diseases. Their lead product candidate, BGE-102, stands out as an innovative small-molecule NLRP3 inhibitor. This treatment aims to address obesity and cardiovascular risk factors, indicating a well-rounded approach to today's pressing health issues.
Clinical Trials and Development
Currently, a Phase 1 SAD/MAD trial is in progress for BGE-102, with initial data expected soon. This trial is a vital step in determining the safety and efficacy of their candidate. Additionally, the company is advancing other programs, including long-acting injectable and oral small-molecule APJ agonists, specifically targeting obesity, which represents a significant concern globally.
About BioAge Labs
Founded with a mission to revolutionize how we approach aging and associated metabolic diseases, BioAge Labs utilizes a proprietary discovery platform grounded in human longevity data. This platform allows the company to identify critical pathways involved in metabolic aging, making strides toward developing effective therapeutic solutions.
Get Involved
Investors and individuals interested in learning more about BioAge Labs are encouraged to visit the company’s website. The site offers resources and detailed information regarding ongoing research initiatives and investment opportunities, showcasing the company’s dedication to transparency and community engagement.
Frequently Asked Questions
What is BioAge Labs, Inc. known for?
BioAge Labs is a biotechnology company focused on developing therapeutic products aimed at treating metabolic diseases by targeting aging biology.
Where will BioAge Labs present its findings?
BioAge Labs will present at the Jefferies Global Healthcare Conference in London.
Who are the key speakers from BioAge Labs at the conference?
The key speakers will be Kristen Fortney, PhD, the CEO, and Dov Goldstein, MD, the CFO.
What is BGE-102?
BGE-102 is BioAge’s lead product candidate, an orally available small-molecule NLRP3 inhibitor aimed at addressing obesity and cardiovascular issues.
How can investors learn more about BioAge Labs?
Investors can visit the BioAge Labs website for insights into ongoing research and investment opportunities.